{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:08:17Z","timestamp":1790698097627,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00259-023-06252-x","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T05:01:56Z","timestamp":1683867716000},"page":"2984-2996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1486-4702","authenticated-orcid":false,"given":"Azadeh","family":"Akhavanallaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery B.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellen","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Roseland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"El-Naqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"5","key":"6252_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7150\/thno.3645","volume":"2","author":"RP Baum","year":"2012","unstructured":"Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy - the Bad Berka experience. Theranostics. 2012;2(5):437\u201347.","journal-title":"Theranostics"},{"issue":"8","key":"6252_CR2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1097\/MNM.0000000000001592","volume":"43","author":"KK Wong","year":"2022","unstructured":"Wong KK, et al. Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors. Nucl Med Commun. 2022;43(8):892\u2013900.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"6252_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, et al. Phase 3 Trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"6252_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7150\/thno.62851","volume":"12","author":"C Miller","year":"2022","unstructured":"Miller C, et al. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics. 2022;12(1):232\u201359.","journal-title":"Theranostics"},{"issue":"3","key":"6252_CR5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, et al. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6252_CR6","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","volume":"49","author":"A Sundl\u00f6v","year":"2022","unstructured":"Sundl\u00f6v A, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"6252_CR7","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","volume":"49","author":"S Xue","year":"2022","unstructured":"Xue S, et al. Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with (177)Lu-PSMA I&T therapy. Eur J Nucl Med Mol Imaging. 2022;49(12):4064\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6252_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","volume":"49","author":"SMB Peters","year":"2022","unstructured":"Peters SMB, et al. [(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49(4):1101\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"6252_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/RLU.0000000000004599","volume":"48","author":"AB Peterson","year":"2023","unstructured":"Peterson AB, et al. 177Lu-DOTATATE Theranostics: predicting renal dosimetry from pretherapy 68Ga-DOTATATE PET and clinical biomarkers. Clin Nucl Med. 2023;48(5):393\u20139.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"6252_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2967\/jnumed.121.262069","volume":"63","author":"D Roth","year":"2022","unstructured":"Roth D, et al. Dosimetric quantities in neuroendocrine tumors over treatment cycles with (177)Lu-DOTATATE. J Nucl Med. 2022;63(3):399\u2013405.","journal-title":"J Nucl Med"},{"issue":"10","key":"6252_CR11","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.2967\/jnumed.117.206649","volume":"59","author":"M Lassmann","year":"2018","unstructured":"Lassmann M, Eberlein U. The relevance of dosimetry in precision medicine. J Nucl Med. 2018;59(10):1494\u20139.","journal-title":"J Nucl Med"},{"issue":"2","key":"6252_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.114.148437","volume":"56","author":"E Ilan","year":"2015","unstructured":"Ilan E, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56(2):177\u201382.","journal-title":"J Nucl Med"},{"issue":"3","key":"6252_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","volume":"95","author":"M \u00d6ks\u00fcz","year":"2014","unstructured":"\u00d6ks\u00fcz M, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289\u2013300.","journal-title":"Diagn Interv Imaging"},{"issue":"12","key":"6252_CR14","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2967\/jnumed.115.162719","volume":"56","author":"V Ambrosini","year":"2015","unstructured":"Ambrosini V, et al. Prognostic Value of 68Ga-DOTANOC PET\/CT SUVmax in patients with neuroendocrine tumors of the pancreas. J Nucl Med. 2015;56(12):1843\u20138.","journal-title":"J Nucl Med"},{"key":"6252_CR15","doi-asserted-by":"crossref","unstructured":"Bruvoll R, et al. Correlations between [(68)Ga]Ga-DOTA-TOC uptake and absorbed dose from [(177)Lu]Lu-DOTA-TATE. Cancers (Basel) 2023;15(4).","DOI":"10.3390\/cancers15041134"},{"issue":"1","key":"6252_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13550-022-00947-2","volume":"12","author":"A Stenvall","year":"2022","unstructured":"Stenvall A, et al. Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy. EJNMMI Res. 2022;12(1):75.","journal-title":"EJNMMI Res"},{"issue":"11","key":"6252_CR17","first-page":"1665","volume":"63","author":"YK Dewaraja","year":"2022","unstructured":"Dewaraja YK, et al. A pipeline for automated voxel dosimetry: application in patients with multi-SPECT\/CT imaging after (177)Lu-peptide receptor radionuclide therapy. J Nucl Med. 2022;63(11):1665\u201372.","journal-title":"J Nucl Med"},{"issue":"1","key":"6252_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2967\/jnumed.118.211094","volume":"60","author":"J Tran-Gia","year":"2019","unstructured":"Tran-Gia J, Lassmann M. Characterization of noise and resolution for quantitative (177)Lu SPECT\/CT with xSPECT Quant. J Nucl Med. 2019;60(1):50\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"6252_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1109\/TNS.2006.889164","volume":"54","author":"SJ Wilderman","year":"2007","unstructured":"Wilderman SJ, Dewaraja YK. Method for fast CT\/SPECT-Based 3D Monte Carlo absorbed dose computations in internal emitter therapy. IEEE Trans Nucl Sci. 2007;54(1):146\u201351.","journal-title":"IEEE Trans Nucl Sci"},{"issue":"5","key":"6252_CR20","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/mp.13497","volume":"46","author":"S Cui","year":"2019","unstructured":"Cui S, et al. Combining handcrafted features with latent variables in machine learning for prediction of radiation-induced lung damage. Med Phys. 2019;46(5):2497\u2013511.","journal-title":"Med Phys"},{"key":"6252_CR21","doi-asserted-by":"crossref","unstructured":"Peduzzi P, et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503\u201310.","DOI":"10.1016\/0895-4356(95)00048-8"},{"issue":"1","key":"6252_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45(1):5\u201332.","journal-title":"Mach Learn"},{"key":"6252_CR23","doi-asserted-by":"crossref","unstructured":"Lou Y, Caruana R, Gehrke J. Intelligible models for classification and regression. In: Proceedings of the 18th ACM SIGKDD international conference on knowledge discovery and data mining. \u00a0Beijing: Association for Computing\u00a0Machinery; 2012. p. 150\u2013158","DOI":"10.1145\/2339530.2339556"},{"issue":"9","key":"6252_CR24","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","volume":"44","author":"M Del Prete","year":"2017","unstructured":"Del Prete M, Buteau FA, Beauregard JM. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490\u2013500.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6252_CR25","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sj\u00f6green Gleisner","year":"2022","unstructured":"Sj\u00f6green Gleisner K, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6252_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5005\/jp-journals-10028-1050","volume":"47","author":"B Singh","year":"2013","unstructured":"Singh B, et al. Can the standardized uptake values derived from diagnostic 68 Ga-DOTATATE PET\/CT imaging predict the radiation dose delivered to the metastatic liver NET lesions on 177 Lu-DOTATATE peptide receptor radionuclide therapy? J Postgrad Med Edu Res. 2013;47:7\u201313.","journal-title":"J Postgrad Med Edu Res"},{"issue":"9","key":"6252_CR27","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2967\/jnumed.119.237818","volume":"61","author":"M Lubberink","year":"2020","unstructured":"Lubberink M, et al. In vivo instability of (177)Lu-DOTATATE during peptide receptor radionuclide therapy. J Nucl Med. 2020;61(9):1337\u201340.","journal-title":"J Nucl Med"},{"issue":"6","key":"6252_CR28","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/RLU.0b013e31823926e5","volume":"37","author":"S Ezziddin","year":"2012","unstructured":"Ezziddin S, et al. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med. 2012;37(6):e141\u20137.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"6252_CR29","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00259-012-2124-x","volume":"39","author":"H H\u00e4nscheid","year":"2012","unstructured":"H\u00e4nscheid H, et al. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging. 2012;39(8):1284\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6252_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2967\/jnumed.119.228072","volume":"61","author":"E Ilan","year":"2020","unstructured":"Ilan E, et al. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using (68)Ga-DOTATOC and (68)Ga-DOTATATE. J Nucl Med. 2020;61(2):217\u201321.","journal-title":"J Nucl Med"},{"issue":"4","key":"6252_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET\/CT. Eur J Nucl Med Mol Imaging. 2013;40(4):514\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6252_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-020-00651-z","volume":"10","author":"YI Kim","year":"2020","unstructured":"Kim YI, et al. Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET\/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res. 2020;10(1):63.","journal-title":"EJNMMI Res"},{"issue":"5","key":"6252_CR33","first-page":"152","volume":"12","author":"E Pauwels","year":"2022","unstructured":"Pauwels E, et al. [(68)Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [(177)Lu]Lu-DOTATATE PRRT. Am J Nucl Med Mol Imaging. 2022;12(5):152\u201362.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"6252_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"6252_CR35","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.ijrobp.2009.02.089","volume":"76","author":"LA Dawson","year":"2010","unstructured":"Dawson LA, et al. Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S108\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"6252_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00259-020-05013-4","volume":"48","author":"A Akhavanallaf","year":"2021","unstructured":"Akhavanallaf A, et al. Whole-body voxel-based internal dosimetry using deep learning. Eur J Nucl Med Mol Imaging. 2021;48(3):670\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06252-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T02:04:48Z","timestamp":1690596288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6252"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06252-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}